Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476112 | 1.00 | SLC6A4 (0.37) | SLC6A4SLC6A2HPGDPKMKMT2A | |
| SCHEMBL5480638 | 0.91 | SLC6A2 (0.45) | SLC6A4SLC6A2 | |
| SCHEMBL5480640 | 0.91 | SLC6A2 (0.45) | SLC6A4SLC6A2 | |
| SCHEMBL5484836 | 0.90 | SLC6A4 (0.36) | SLC6A4SLC6A2PKML3MBTL1 | |
| SCHEMBL4718224 | 0.90 | SLC6A4 (0.36) | SLC6A4SLC6A2PKML3MBTL1 | |
| SCHEMBL4719867 | 0.87 | SLC6A4 (0.37) | SLC6A4SLC6A2PKM | |
| SCHEMBL5484992 | 0.87 | SLC6A4 (0.37) | SLC6A4SLC6A2PKM | |
| SCHEMBL4079167 | 0.87 | SLC6A4 (0.36) | SLC6A4SLC6A2PKMHTT | |
| SCHEMBL4079165 | 0.87 | SLC6A4 (0.36) | SLC6A4SLC6A2PKMHTT | |
| SCHEMBL4088906 | 0.83 | SLC6A4 (0.48) | SLC6A4SLC6A2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931631-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth a Corporation of the State of Delaware (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007041023-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | COMT, PNMT, GLS | SLC6A4 16/4885SLC6A2 8/4885HPGD 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.